Effect of Intravenous Iron Sucrose in Peritoneal Dialysis

Although adamant analysis is capital to optimize use of erythropoiesis-stimulating agents (ESA), randomized, controlled trials accept heretofore been bare to appraise anxiously the ability of intravenous adamant as an accessory to ESA analysis in peritoneal dialysis (PD) patients.
In a multicenter trial, patients who had anemia, PD-dependent abiding branch disease, abiding ESA therapy, and a ample ambit of adamant cachet (ferritin ≤500 ng/ml, transferrin assimilation ≤25%) were about assigned to accept either 1 g of Iron Sucrose intravenously in three disconnected doses (300 mg over 1.5 h on canicule 1 and 15, 400 mg over 2.5 h on day 29) or no added iron. No austere adverse biologic contest occurred afterwards intravenous adamant administration. The primary end point, aiguille claret increase, was college (1.3 ± 1.1 against 0.7 ± 1.1, beggarly ± SD; P = 0.0028), and anemia action (transfusion, access in ESA dose, or intravenous adamant analysis not alleged for in protocol) occurred after (P = 0.0137) and beneath generally in intravenous iron–treated patients compared with basic ascendancy capacity (one of 66 [1.3%] against 5 of 30 [16.7%]).
Among patients who did not crave intervention, iron-treated patients showed a affected net ESA dosage abatement compared with basic ascendancy subjects. Baseline adamant cachet did not adumbrate admiration to intravenous adamant therapy. Intravenous Iron Sucrose is an able accessory to ESA analysis in bloodless patients with PD-dependent abiding branch ache and is administered cautiously as 300 mg over 1.5 h or 400 mg over 2.5 h. Evidence of adamant absence at baseline is not appropriate to authenticate intravenous adamant efficacy.